This Biotech Was Quietly Bought Before a $58 Per Share Takeout
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders
Contrasting Solid Biosciences (NASDAQ:SLDB) & Rapt Therapeutics (NASDAQ:RAPT)
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC is Investigating Whether NWE, DHIL, RAPT are Obtaining Fair Prices for its Shareholders
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s Investigations
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)
Rapt Therapeutics (NASDAQ:RAPT) Reaches New 52-Week High – Should You Buy?
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout
S&P 500 Records Worst Session Since October: Investor Sentiment Dips, Fear & Greed Index In 'Neutral' Zone
Halper Sadeh LLC Encourages CVGW, RAPT, CFLT Shareholders to Contact the Firm to Discuss Their Rights
Why Rapt Therapeutics Stock Soared Today
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RAPT Therapeutics, Inc. (NASDAQ: RAPT)
Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK
Shareholder Alert: The Ademi Firm investigates whether RAPT Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
Dow Jones Today: Stocks Dive, Bond Yields Soar After Trump Threatens New Tariffs Over Greenland; Gold, Silver Hit Fresh All-Time Highs
RAPT Therapeutics shares surge 64% as GSK agrees $2.2B acquisition
GSK to buy food allergy drug maker RAPT in $2.2bn deal
This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up.
RAPT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of RAPT Therapeutics, Inc. is Fair to Shareholders
GSK To Acquire RAPT Therapeutics In $2.2 Billion Bet On Food Allergy Breakthrough
GSK to buy RAPT Therapeutics for $2.2 billion
RAPT Therapeutics, Inc. (RAPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Rapt Therapeutics (NASDAQ:RAPT) Shares Gap Up – Time to Buy?
RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rapt Therapeutics (NASDAQ:RAPT) & Atea Pharmaceuticals (NASDAQ:AVIR) Head-To-Head Contrast
RAPT Therapeutics: Strong Promise In Immunology, Looking Like An Opportunity At These Prices
RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria Transcript
RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
Peanut Allergy Clinical Trial Pipeline: Insights into a Growing Landscape with 12+ Companies Advancing Novel Treatments| DelveInsight
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 101.02%: Read This Before Placing a Bet
Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross
RAPT Therapeutics Reports Second Quarter 2025 Financial Results